The role of protein misfolding in the pathogenesis of human diseases

IUBMB Life

Volumn 56, Issue 3, 2004, Pages 119-123

  Ellisdon, Andrew M ^a   Bottomley, Stephen P ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Amyloid fibrils; Conformational disease; Polyglutamine; Protein aggregation; Protein folding; Protein misfolding

Indexed keywords

AMYLOID; PEPTIDE; POLYGLUTAMINE; PROTEIN;

ALPHA 1 ANTITRYPSIN DEFICIENCY; ALZHEIMER DISEASE; CONFORMATIONAL TRANSITION; DISEASE PREDISPOSITION; HUMAN; HUNTINGTON CHOREA; KINETICS; PATHOGENESIS; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN FOLDING; PROTEIN MISFOLDING; PROTEIN STRUCTURE; QUALITY CONTROL; REVIEW; RISK FACTOR; STRUCTURE ANALYSIS; THERMODYNAMICS;

AMYLOID; GENETIC DISEASES, INBORN; HUMANS; PEPTIDES; PROTEIN CONFORMATION; PROTEIN FOLDING;

EID: 2442714050     PISSN: 15216543     EISSN: None     Source Type: Journal    
DOI: 10.1080/15216540410001674003     Document Type: Review

References (42)

1. Anfinsen, C. B. (1973) Principles that govern the folding of protein chains. Science 181, 223-230.
2. Sherman, M. Y., and Goldberg, A. L. (2001) Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases. Neuron 29, 15-32.
3. Hartl, F. U. (1996) Molecular chaperones in cellular protein folding. Nature 381, 571-579.
4. Kostova, Z., and Wolf, D. H. (2003) For whom the bell tolls: protein quality control of the endoplasmic reticulum and the ubiquitin-proteasome connection. Embo J. 22, 2309-2317.
5. Ciechanover, A., and Brundin, P. (2003) The ubiquitin proteasome system in neurodegenerative diseases. Sometimes the chicken, sometimes the egg. Neuron 40, 427-446.
6. Stefani, M., and Dobson, C. M. (2003) Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution. J. Mol. Med. 81, 678-699.
7. Jensen, T. J., Loo, M. A., Pind, S., Williams, D. B., Goldberg, A. L., and Riordan, J. R. (1995) Multiple proteolytic systems, including the proteasome, contribute to CFTR processing. Cell 83, 129-135.
8. Ward, C. L., Omura, S., and Kopito, R. R. (1995) Degradation of CFTR by the ubiquitin-proteasome pathway. Cell 83, 121-127.
9. Carrell, R. W., and Lomas, D. A. (1997) Conformational disease. Lancet 350, 134-138.
10. DiFiglia, M., Sapp, E., Chase, K. O., Davies, S. W., Bates, G. P., Vonsattel, J. P., and Aronin, N. (1997) Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277, 1990-1993.
11. Serpell, L. C., Sunde, M., and Blake, C. C. (1997) The molecular basis of amyloidosis. Cell. Mol. Life Sci. 53, 871-887.
12. Serpell, L. C., Sunde, M., Benson, M. D., Tennent, G. A., Pepys, M. B., and Fraser, P. E. (2000) The protofilament substructure of amyloid fibrils. J. Mol. Biol. 300, 1033-1039.
13. Scherzinger, E., Sittler, A., Schweiger, K., Heiser, V., Lurz, R., Hasenbank, R., Bates, G. P., Lehrach, H., and Wanker, E. E. (1999) Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: implications for Huntington's disease pathology. Proc. Natl. Acad. Sci. USA 96, 4604-4609.
14. Wood, S. J., Wypych, J., Steavenson, S., Louis, J. C., Citron, M., and Biere, A. L. (1999) Alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease. J. Biol. Chem. 274, 19509-19512.
15. Friedhoff, P., von Bergen, M., Mandelkow, E. M., Davies, P., and Mandelkow, E. (1998) A nucleated assembly mechanism of Alzheimer paired helical filaments. Proc. Natl. Acad. Sci. USA 95, 15712-15717.
16. Horwich, A. (2002) Protein aggregation in disease: a role for folding intermediates forming specific multimeric interactions. J. Clin. Invest. 110, 1221-1232.
17. Kelly, J. W. (1998) The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways. Curr. Opin. Struct. Biol. 8, 101-106.
18. Harper, J. D., Wong, S. S., Lieber, C. M., and Lansbury, P. T. (1997) Observation of metastable Abeta amyloid protofibrils by atomic force microscopy. Chem. Biol. 4, 119-125.
19. Walsh, D. M., Lomakin, A., Benedek, G. B., Condron, M. M., and Teplow, D. B. (1997) Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate. J. Biol. Chem. 272, 22364-22372.
20. Lashuel, H. A., Lai, Z., and Kelly, J. W. (1998) Characterization of the transthyretin acid denaturation pathways by analytical ultracentrifugation: implications for wild-type, V30M, and L55P amyloid fibril formation. Biochemistry 37, 17851-17864.
21. Poirier, M. A., Li, H., Macosko, J., Cai, S., Amzel, M., and Ross, C. A. (2002) Huntingtin spheroids and protofibrils as precursors in polyglutamine fibrilization. J. Biol. Chem. 277, 41032-41037.
22. Conway, K. A., Lee, S. J., Rochet, J. C., Ding, T. T., Williamson, R. E., and Lansbury, P. T., Jr. (2000) Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl. Acad. Sci. USA 97, 571-576.
23. Kelly, J. W. (1996) Alternative conformations of amyloidogenic proteins govern their behavior. Curr. Opin. Struct. Biol. 6, 11-17.
24. Lai, Z., Colon, W., and Kelly, J. W. (1996) The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid. Biochemistry 35, 6470-6482.
25. Chiti, F., Webster, P., Taddei, N., Clark, A., Stefani, M., Ramponi, G., and Dobson, C. M. (1999) Designing conditions for in vitro formation of amyloid protofilaments and fibrils. Proc. Natl. Acad. Sci. USA 96, 3590-3594.
26. Guijarro, J. I., Sunde, M., Jones, J. A., Campbell, I. D., and Dobson, C. M. (1998) Amyloid fibril formation by an SH3 domain. Proc. Natl. Acad. Sci. USA 95, 4224-4228.
27. Chow, M. K., Paulson, H. L., and Bottomley, S. P. (2003) Destabilization of a non-pathological variant of Ataxin-3 results in fibrillogenesis via a partially folded intermediate: a model for misfolding in polyglutamine disease. J. Mol. Biol. 335, 333-341.
28. Ahmad, A., Millett, I. S., Doniach, S., Uversky, V. N., and Fink, A. L. (2003) Partially folded intermediates in insulin fibrillation. Biochemistry 42, 11404-11416.
29. Rochet, J. C., and Lansbury, P. T., Jr. (2000) Amyloid fibrillogenesis: themes and variations. Curr. Opin. Struct. Biol. 10, 60-68.
30. Burke, M. G., Woscholski, R., and Yaliraki, S. N. (2003) Differential hydrophobicity drives self-assembly in Huntington's disease. Proc. Natl. Acad. Sci. USA 100, 13928-13933.
31. Schmittschmitt, J. P., and Scholtz, J. M. (2003) The role of protein stability, solubility, and net charge in amyloid fibril formation. Protein Sci. 12, 2374-2378.
32. Pepys, M. B. (2001) Pathogenesis, diagnosis and treatment of systemic amyloidosis. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 356, 203-210; discussion 210-211.
33. Zoghbi, H. Y., and Orr, H. T. (2000) Glutamine repeats and neurodegeneration. Annu. Rev. Neurosci. 23, 217-247.
34. Gutekunst, C. A., Li, S. H., Yi, H., Mulroy, J. S., Kuemmerle, S., Jones, R., Rye, D., Ferrante, R. J., Hersch, S. M., and Li, X. J. (1999) Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. J. Neurosci. 19, 2522-2534.
35. Bucciantini, M., Giannoni, E., Chiti, F., Baroni, F., Formigll, L., Zurdo, J., Taddei, N., Ramponi, G., Dobson, C. M., and Stefani, M. (2002) Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 416, 507-511.
36. Nilsberth, C., Westlind-Danielsson, A., Eckman, C. B., Condron, M. M., Axelman, K., Forsell, C., Stenh, C., Luthman, J., Teplow, D. B., Younkin, S. G., et al. (2001) The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. Nat. Neurosci. 4, 887-893.
37. Li, J., Uversky, V. N., and Fink, A. L. (2001) Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein. Biochemistry 40, 11604-11613.
38. Hartley, D. M., Walsh, D. M., Ye, C. P., Diehl, T., Vasquez, S., Vassilev, P. M., Teplow, D. B., and Selkoe, D. J. (1999) Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J. Neurosci. 19, 8876-8884.
39. Walsh, D. M., Hartley, D. M., Kusumoto, Y., Fezoui, Y., Condron, M. M., Lomakin, A., Benedek, G. B., Selkoe, D. J., and Teplow, D. B. (1999) Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. J. Biol. Chem. 274, 25945-25952.
40. Yang, W., Dunlap, J. R., Andrews, R. B., and Wetzel, R. (2002) Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells. Hum. Mol. Genet. 11, 2905-2917.
41. Sanchez, I., Mahlke, C., and Yuan, J. (2003) Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature 421, 373-379.
42. Soto, C. (2003) Unfolding the role of protein misfolding in neurodegenerative diseases. Nat. Rev. Neurosci. 4, 49-60.